Linaclotide

CHEMBL3301675 Phase 4 Approuvé Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1526.8 g/mol
LogP
-6.8
Phase
4

A guanylate cyclase-C agonist used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. It works locally in the intestine to increase fluid secretion and accelerate bowel transit without significant systemic absorption.

Masse moléculaire

1526,8000 g/mol

LogP

-6,80

TPSA

726,00 Ų

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Mécanisme d'action

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2

InChI

InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1

Molecular Formula

C59H79N15O21S6

HBD / HBA

19 / 28

Liaisons Rotatives

13

Atomes Lourds

101

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A guanylate cyclase-C agonist used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. It works locally in the intestine to increase fluid secretion and accelerate bowel transit without significant systemic absorption.

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Yes, Linaclotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301675. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16158208. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.